---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-23-001126"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T17:45:09.205564+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexaria receives Nasdaq bid price deficiency notice; 180 days to regain compliance

## Summary
- Nasdaq letter dated June 22, 2023 cites LEXX not meeting $1.00 bid price requirement.
- Company has until December 19, 2023 to close at or above $1.00 for 10 consecutive days.
- If not compliant, may qualify for additional 180-day period; could consider reverse stock split.
- No immediate effect on listing; common stock continues trading on Nasdaq under LEXX.
- Company intends to monitor bid price and evaluate options but no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001640334-23-001126
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033423001126/0001640334-23-001126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033423001126/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-23-001126
- JSON: https://secwatch.observer/filing/0001640334-23-001126.json
- Plain text: https://secwatch.observer/filing/0001640334-23-001126.txt

## Key facts
- Listing & Compliance Notices
  Lexaria Bioscience Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: June 22, 2023, Lexaria Bioscience Corp. (the “Company”) received a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Bid Price Deficiency Notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Capital Market un
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348362/000164033423001126/0001640334-23-001126-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.